{"id":742143,"date":"2011-02-03T07:00:00","date_gmt":"2011-02-03T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fourth-quarter-and-full-year-2010-financial-results\/"},"modified":"2026-08-10T13:01:19","modified_gmt":"2026-08-10T17:01:19","slug":"merck-announces-fourth-quarter-and-full-year-2010-financial-results","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fourth-quarter-and-full-year-2010-financial-results\/","title":{"rendered":"Merck Announces Fourth Quarter and Full Year 2010 Financial Results"},"content":{"rendered":"<ul>\n<li>         Company Reports Double-Digit Non-GAAP EPS Growth in the Fourth Quarter       <\/li>\n<li>         Fourth Quarter Non-GAAP EPS of $0.88, Excluding Certain Items; GAAP          EPS of $(0.17); Full Year 2010 Non-GAAP EPS of $3.42, Excluding          Certain Items; GAAP EPS of $0.28       <\/li>\n<li>         Continued Strong Global Growth from JANUVIA\/JANUMET, SINGULAIR,          ISENTRESS, REMICADE       <\/li>\n<li>         Realized More than $2 Billion in Net Synergy Savings in 2010; On Track          to Reach $3.5 Billion in Annual Savings by End of 2012       <\/li>\n<li>         Company Withdraws Previous Long-Term Non-GAAP EPS Target; Full Year          2011 Non-GAAP EPS Target of $3.64 to $3.76, Excluding Certain Items;          GAAP EPS Range of $2.05 to $2.33       <\/li>\n<\/ul>\n<p>WHITEHOUSE STATION, N.J.&#8211;(BUSINESS WIRE)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,        today announced financial results for the fourth quarter and full year        of 2010. The company reported non-GAAP (generally accepted accounting        principles) earnings per share (EPS) for the fourth quarter of $0.88,        which excludes purchase accounting adjustments, restructuring costs and        merger-related expenses. The purchase accounting adjustments include a        $1.7 billion pre-tax charge related to its vorapaxar clinical research        program. Fourth quarter GAAP EPS was $(0.17). Merck also announced full        year 2010 non-GAAP EPS of $3.42, excluding certain items, and full year        GAAP EPS of $0.28.     <\/p>\n<p>       Worldwide sales for the fourth quarter of 2010 were $12.1 billion. GAAP        net loss<sup>1<\/sup> for the fourth quarter was $531 million. For the        full year of 2010, worldwide sales were $46.0 billion and GAAP net        income was $861 million.     <\/p>\n<p>       A reconciliation of EPS as reported in accordance with GAAP to non-GAAP        EPS that excludes certain items is provided in the table that follows.        The fourth quarter and full year 2009 results below include legacy        Schering-Plough results only for the post-merger period, which began on        Nov. 4, 2009.     <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\">\n<p class=\"bwcellpmargin\">             <b>Fourth<\/b><br \/><b>Quarter<\/b><br \/><b>2010<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\">\n<p class=\"bwcellpmargin\">             <b>Fourth<\/b><br \/><b>Quarter<\/b><br \/><b>2009<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Year Ended<\/b><br \/><b>Dec. 31,<\/b><br \/><b>2010<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\">\n<p class=\"bwcellpmargin\">             <b>Year Ended<\/b><br \/><b>Dec. 31,<\/b><br \/><b>2009<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>GAAP EPS<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           <b>$<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>(0.17<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           <b>)<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           <b>$<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>2.35<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           <b>$<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>0.28<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           <b>$<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>5.65<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             EPS difference<sup>2<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1.05         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (1.56         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           3.14         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (2.40         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Non-GAAP EPS that excludes certain items, listed below<\/b><sup><b>3<\/b><\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>$<\/b>           <\/p>\n<\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>0.88<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>$<\/b>           <\/p>\n<\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>0.79<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>$<\/b>           <\/p>\n<\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>3.42<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>$<\/b>           <\/p>\n<\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>3.25<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\">\n<p class=\"bwcellpmargin\">             <b>Fourth<\/b><br \/><b>Quarter<\/b><br \/><b>2010<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\">\n<p class=\"bwcellpmargin\">             <b>Fourth<\/b><br \/><b>Quarter<\/b><br \/><b>2009<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\">\n<p class=\"bwcellpmargin\">             <b>Year Ended<\/b><br \/><b>Dec. 31,<\/b><br \/><b>2010<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\">\n<p class=\"bwcellpmargin\">             <b>Year Ended<\/b><br \/><b>Dec. 31,<\/b><br \/><b>2009<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Purchase accounting adjustments<sup>4<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           3,431         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,286         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           9,007         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,286         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Merger restructuring program         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           298         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,460         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,795         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,460         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Costs related to other restructuring programs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           56         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           36         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           191         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           521         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Merger-related costs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           160         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           288         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           396         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           544         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Legal reserve         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           950         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Gain on AstraZeneca&#8217;s asset option exercise         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (443         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Gain associated with Merck\/Schering-Plough partnership         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (7,530         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (7,530         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Gain from sale of interest in Merial         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (400         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8212;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (3,163         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Net decrease (increase) in income before taxes         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           3,945         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (3,860         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           11,896         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (5,882         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Income tax (benefit) expense<sup>5<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (658         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (458         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (2,042         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           390         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Decrease (increase) in net income         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           3,287         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (4,318         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           9,854         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (5,492         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           )         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>EPS difference<\/b><sup>2<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           <b>$<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>1.05<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           <b>$<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>(1.56<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           <b>)<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           <b>$<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>3.14<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">           <b>$<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>(2.40<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           <b>)<\/b>         <\/td>\n<\/tr>\n<\/table>\n<p>       &#8220;Merck today reported a high quality fourth quarter characterized by        strong revenue performance, significant cost reductions and double-digit        earnings growth,&#8221; said Kenneth C. Frazier, president and chief executive        officer. &#8220;These results clearly demonstrate the benefits of the        post-merger Merck with our broader product portfolio, robust late-stage        pipeline and expanded global footprint.     <\/p>\n<p>       &#8220;Looking ahead, our focus will be on delivering sustainable, profitable        top-line growth,&#8221; Frazier added. &#8220;To do that, Merck will continue to        innovate, make disciplined investments in our business and continue to        drive out inefficiencies in our operations. Coming out of our first year        as a combined company, Merck employees in markets all over the world are        energized and excited about capitalizing on the many new opportunities        we have to bring value to patients, customers and shareholders.&#8221;     <\/p>\n<p>       <b>Select Business Highlights<\/b>     <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">         Merck is currently launching more than 10 medicines in key markets          around the world.       <\/li>\n<li class=\"bwlistitemmargb\">         The company continues to make progress in its pipeline, including:\n<ul>\n<li class=\"bwlistitemmargb\">             Boceprevir, an investigational oral hepatitis C virus (HCV)              protease inhibitor, was granted Priority Review status by the U.S.              Food and Drug Administration (FDA) and accelerated assessment              status by the European Union.           <\/li>\n<li class=\"bwlistitemmargb\">             The FDA accepted a new drug application for an investigational              extended-release formulation of JANUMET (sitagliptin\/metformin              HCI).           <\/li>\n<li class=\"bwlistitemmargb\">             In the Phase III DEFINE study with Merck&#8217;s investigational CETP              inhibitor, anacetrapib, patients with coronary heart disease or              CHD risk equivalents showed no significant differences from              placebo in the primary safety measures studied. In addition, at 24              weeks, anacetrapib decreased LDL-C (bad cholesterol) by 40 percent              and increased HDL-C (good cholesterol) by 138 percent in patients              already treated with a statin and at guideline-recommended LDL-C              goal.           <\/li>\n<li class=\"bwlistitemmargb\">             Top-line results for Phase III SUCCEED trial of ridaforolimus              showed it met the primary endpoint in patients with metastatic              soft-tissue or bone sarcomas.           <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">         Also in the quarter, the company announced the results of the SHARP          trial, which showed that VYTORIN (ezetimibe\/simvastatin) significantly          reduced major vascular events in patients with chronic kidney disease.          The SHARP study is the first and only prospective clinical study in          patients with chronic kidney disease to show that an LDL          cholesterol-lowering medicine reduced major vascular and          atherosclerotic events.       <\/li>\n<li class=\"bwlistitemmargb\">         Merck continued its commitment to develop biosimilars through an          alliance with Parexel International Corporation.       <\/li>\n<li class=\"bwlistitemmargb\">         The company acquired SmartCells, Inc., a privately held company          developing a glucose responsive insulin formulation potentially for          the treatment of type 1 and type 2 diabetes.       <\/li>\n<li class=\"bwlistitemmargb\">         The company completed a $2 billion public offering of senior notes.          Proceeds will be used for general corporate purposes.       <\/li>\n<\/ul>\n<p>       <b>Fourth Quarter and Full Year Sales Results<\/b>     <\/p>\n<p>       The following supplemental combined 2009 non-GAAP sales are adjusted to        reflect a full quarter and a full year of legacy Merck and legacy        Schering-Plough combined results. See Explanatory Note on page 12 of        this release for further information.     <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>GAAP<\/b><br \/><b>4Q10<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>GAAP<\/b><br \/><b>4Q09<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Adj.<\/b><br \/><b>4Q09<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Supp.<\/b><br \/><b>Comb.<\/b><br \/><b>Non-<\/b><br \/><b>GAAP<\/b><br \/><b>4Q09<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>GAAP<\/b><br \/><b>FY10<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>GAAP<\/b><br \/><b>FY09<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Adj.<\/b><br \/><b>FY09<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Supp.<\/b><br \/><b>Comb.<\/b><br \/><b>Non-<\/b><br \/><b>GAAP<\/b><br \/><b>FY09<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Total Sales         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $12,094         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 10,093         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 2,123         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 12,216         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 45,987         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $27,428         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 18,537         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ 45,964         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Human Health<sup>6<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           10,581         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           9,072         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,733         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           10,805         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           39,811         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           25,236         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           14,862         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           40,098         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Animal Health         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           815         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           494         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           265         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           759         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,941         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           494         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,222         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,716         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Consumer Care<sup>6<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           251         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           149         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           83         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           232         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,342         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           149         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,131         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,281         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Other Revenues<sup>7<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           447         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           379         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           41         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           420         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,893         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,548         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           322         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,870         <\/td>\n<\/tr>\n<\/table>\n<p>       <b>Fourth Quarter and Full Year Expense and Other Information<\/b>     <\/p>\n<p>       The fourth quarter and full year 2010 results below reflect the        performance of the combined company. The increases in 2010 non-GAAP        expenses are largely due to the inclusion of legacy Schering-Plough        post-merger results.     <\/p>\n<p>       The costs detailed below on a GAAP basis during the fourth quarter of        2010 totaled $12.7 billion and include $3.9 billion of purchase        accounting adjustments, restructuring costs and merger-related costs.     <\/p>\n<p>       On a full year 2010 GAAP basis, these costs totaled $43.6 billion and        include $11.4 billion in purchase accounting adjustments, restructuring        costs and merger-related costs. See below for 2009 comparable periods.     <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwsinglebottom\" colspan=\"11\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignc\" colspan=\"11\">           <b>Fourth Quarter<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"5\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"5\">           <b>Included in expenses for the period<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>GAAP<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Purchase<\/b><br \/><b>Accounting<\/b><br \/><b>Adjustments<\/b><sup><b>4<\/b><\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Restructuring<\/b><br \/><b>Costs<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Merger-<\/b><br \/><b>Related<\/b><br \/><b>Costs<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Non-GAAP<\/b><sup><b>3<\/b><\/sup>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           <b>2010<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Materials and production         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $4,440         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $1,206         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $105         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $3,129         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Marketing and administrative         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           3,579         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           13         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           160         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           3,406         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Research and development         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           4,517         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,225         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           115         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,177         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Restructuring costs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           121         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           121         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           <b>2009<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Materials and production         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $4,901         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $2,286         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $19         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $2,596         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Marketing and administrative         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           3,455         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           265         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           3,190         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Research and development         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,971         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           (13)         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,984         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Restructuring costs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,490         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,490         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwsinglebottom\" colspan=\"11\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignc\" colspan=\"11\">           <b>Full Year<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"5\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"5\">           <b>Included in expenses for the period<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>GAAP<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Purchase<\/b><br \/><b>Accounting<\/b><br \/><b>Adjustments<\/b><sup><b>4<\/b><\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Restructuring<\/b><br \/><b>Costs<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Merger-<\/b><br \/><b>Related<\/b><br \/><b>Costs<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Non-GAAP<\/b><sup><b>3<\/b><\/sup>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           <b>2010<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Materials and production         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $18,396         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $6,566         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $430         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $11,400         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Marketing and administrative         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           13,245         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           143         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           379         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           12,723         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Research and development         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           10,991         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           2,441         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           428         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           8,122         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Restructuring costs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           985         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           985         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           <b>2009<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Materials and production         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $9,019         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $2,286         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $115         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $ &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $6,618         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Marketing and administrative         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           8,543         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           371         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           8,172         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Research and development         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           5,845         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           232         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           5,613         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           Restructuring costs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,634         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           1,634         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           &#8211;         <\/td>\n<\/tr>\n<\/table>\n<p>       The gross margin was 63.3 percent for the fourth quarter and 60.0        percent for the full year of 2010, reflecting 10.8 and 15.2 percentage        point unfavorable impacts, respectively, from the purchase accounting        adjustments and restructuring costs noted above.     <\/p>\n<p>       Equity income from affiliates was $171 million in the fourth quarter and        $587 million for the full year of 2010. Equity income from affiliates        primarily includes the AstraZeneca LP, Johnson &amp; Johnson Merck Consumer        Pharmaceuticals Company and Sanofi Pasteur MSD partnerships, and no        longer reflects any contribution from the Merck\/Schering-Plough        partnership or from Merial Limited (Merial).     <\/p>\n<p>       Other (income) expense, net was $309 million of expense in the fourth        quarter of 2010 which includes $120 million of exchange losses due to        the Venezuelan currency devaluation. Other (income) expense, net was        $1.3 billion of expense for the full year of 2010, which reflects a        previously disclosed $950 million legal reserve, $200 million of        exchange losses due to Venezuelan currency devaluations and $443 million        of income recognized upon AstraZeneca&#8217;s asset option exercise in the        second quarter. Other (income) expense, net for the fourth quarter of        2009 was $7.8 billion of income primarily reflecting a $7.5 billion gain        associated with obtaining a controlling interest in the        Merck\/Schering-Plough partnership. Other (income) expense, net for the        full year of 2009 was $10.7 billion of income which included the $7.5        billion gain associated with obtaining a controlling interest in the        Merck\/Schering-Plough partnership, and a $3.2 billion gain from the sale        of Merck&#8217;s interest in Merial.     <\/p>\n<p>       The GAAP effective tax rate of 28.7 percent for the fourth quarter of        2010 reflects the impact of purchase accounting adjustments,        restructuring costs and merger-related costs. The non-GAAP effective tax        rate, which excludes these items, was 14.1 percent for the quarter. Both        the GAAP and non-GAAP effective tax rates reflect a benefit of        approximately $80 million as a result of the fourth quarter 2010        enactment of the tax extenders legislation, including the R&amp;D tax credit.     <\/p>\n<p>       <b>Financial Targets<\/b>     <\/p>\n<p>       The company expects full year 2011 revenue to grow in the low to        mid-single digit percent range from the base of $46.0 billion in the        full year 2010.     <\/p>\n<p>       In 2011, Merck is targeting full year non-GAAP EPS in the range of $3.64        to $3.76, excluding certain items, and a 2011 GAAP EPS range of $2.05 to        $2.33. The 2011 non-GAAP EPS range excludes purchase accounting        adjustments, restructuring and merger-related costs.     <\/p>\n<p>       EPS and other financial targets for 2011 assume that Merck will retain        full rights to REMICADE and SIMPONI in the applicable markets. The 2011        targets also assume that the results from the animal health business        will continue to be reported in net sales and operating expenses for the        entire year, and these targets will be adjusted upon formation of the        joint venture.     <\/p>\n<p>       A reconciliation of anticipated 2011 EPS as reported in accordance with        GAAP to non-GAAP EPS that excludes certain items is provided in the        table below.     <\/p>\n<p>       Non-GAAP research and development expense, which excludes joint        ventures, is anticipated to be approximately $8.1 billion to $8.5        billion for the full year of 2011. This target excludes restructuring        costs and in-process R&amp;D impairment charges.     <\/p>\n<p>       Merck estimates that its consolidated non-GAAP 2011 tax rate will be        approximately 20 percent to 22 percent.     <\/p>\n<p>       Given industry pressures such as greater E.U. austerity measures and the        additional impact of U.S. health care reform, as well as developments in        its vorapaxar clinical program, the company has withdrawn its previous        long-term target of high single-digit non-GAAP EPS compound annual        growth rate from 2009 to 2013.     <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">           <b>Full Year 2011<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           <b>GAAP EPS<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\">           <b>$2.05 to $2.33<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             EPS difference<sup>2<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\">           $1.59 to $1.43         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>Non-GAAP EPS that excludes certain items,<\/b><br \/><b>listed              below<\/b>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\">           <b>$3.64 to $3.76<\/b>         <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\">           <b>Full Year 2011<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Purchase accounting adjustments         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr bwsinglebottom\">           $4,800 to $4,500         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Costs related to restructuring programs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr bwsinglebottom\">           900 to 700         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Merger-related costs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr bwsinglebottom\">           200 to 100         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Net decrease (increase) in income before taxes         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr bwsinglebottom\">           5,900 to 5,300         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             Income tax (benefit) expense<sup>8<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr bwsinglebottom\">           (980) to (860)         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           Decrease (increase) in net income         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr bwsinglebottom\">           $4,920 to $4,440         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>EPS difference<\/b><sup>2<\/sup>           <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             <b>$1.59 to $1.43<\/b>           <\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>       <b>Product Performance \u2013 Human Health<\/b>     <\/p>\n<p>       <i>Bone, Respiratory, Immunology and Dermatology<\/i>     <\/p>\n<p>       Worldwide sales of SINGULAIR (montelukast sodium), a once-a-day oral        medicine indicated for the chronic treatment of asthma and the relief of        symptoms of allergic rhinitis, were $1.3 billion for the fourth quarter        of 2010, an increase of 7 percent compared with the fourth quarter of        2009. Full year worldwide sales for SINGULAIR were $5.0 billion, a 7        percent increase compared with the prior year.     <\/p>\n<p>       Global sales of NASONEX (mometasone furoate monohydrate) nasal spray, an        inhaled nasal corticosteroid for the treatment of nasal allergy        symptoms, were $303 million for the fourth quarter and $1.2 billion for        the full year of 2010.     <\/p>\n<p>       Sales of REMICADE (infliximab) were $710 million for the fourth quarter        and $2.7 billion for the full year of 2010. REMICADE is a treatment for        inflammatory diseases. Sales of SIMPONI (golimumab) were $42 million for        the fourth quarter and $97 million for the full year of 2010. SIMPONI, a        once-monthly, subcutaneous treatment for certain inflammatory diseases,        has been launched in 18<b> <\/b>countries and launches in other        international markets are planned. A subsidiary of Merck has exclusive        marketing rights for REMICADE and SIMPONI outside the United States        except in China, Japan, Indonesia, Taiwan and Hong Kong. The        subsidiary&#8217;s rights to market REMICADE and SIMPONI are the subject of an        ongoing arbitration process with Centocor, which has been previously        disclosed.     <\/p>\n<p>       <i>Cardiovascular<\/i>     <\/p>\n<p>       Global sales of ZETIA (ezetimibe) and VYTORIN (ezetimibe\/simvastatin),        the company&#8217;s cholesterol-lowering medicines, were $629 million and $562        million, respectively, for the fourth quarter of 2010. Annual worldwide        sales of ZETIA for 2010 were $2.3 billion and $2.0 billion for VYTORIN.     <\/p>\n<p>       <i>Diabetes and Obesity<\/i>     <\/p>\n<p>       JANUVIA (sitagliptin), Merck&#8217;s DPP-4 inhibitor for the treatment of type        2 diabetes, recorded worldwide sales of $675 million during the fourth        quarter of 2010, representing a 21 percent increase compared with the        same quarter in 2009. JANUMET (sitagliptin\/metformin hydrochloride), a        single tablet that targets all three key defects of type 2 diabetes,        achieved worldwide sales of $288 million during the quarter, an increase        of 42 percent compared with the fourth quarter 2009. The JANUVIA\/JANUMET        combined franchise had sales of $962 million during the fourth quarter        of 2010, an increase of 27 percent compared to the same quarter in 2009.        JANUVIA reached $2.4 billion in worldwide sales in 2010, while JANUMET        achieved $954 million in global sales for the year. The combined        JANUVIA\/JANUMET franchise had sales of $3.3 billion for the full year of        2010, an increase of 29 percent.     <\/p>\n<p>       <i>Infectious Disease<\/i>     <\/p>\n<p>       ISENTRESS (raltegravir), an HIV integrase inhibitor for use in        combination with other antiretroviral agents for the treatment of HIV-1        infection, reported worldwide sales of $313 million for the fourth        quarter of 2010, an increase of 34 percent compared with the fourth        quarter of 2009. Global sales of ISENTRESS for the full year of 2010        were $1.1 billion, a 45 percent increase compared with the prior year.     <\/p>\n<p>       Worldwide sales of PEGINTRON (peginterferon alfa-2b) for chronic        hepatitis C were $198 million for the fourth quarter and $737 million        for the full year of 2010.     <\/p>\n<p>       <i>Diversified Brands<\/i>     <\/p>\n<p>       Merck&#8217;s diversified brands are human health pharmaceutical products that        are approaching the expiration of their marketing exclusivity or are no        longer protected by patents in developed markets, but continue to be a        core part of the company&#8217;s offering in other markets around the world.     <\/p>\n<p>       Global sales of Merck&#8217;s antihypertensive medicines, COZAAR (losartan        potassium) and HYZAAR<sup>9<\/sup> (losartan potassium and        hydrochlorothiazide), were $415 million for the fourth quarter of 2010,        representing a 57 percent decrease compared with the fourth quarter of        2009. Full year worldwide sales for COZAAR\/HYZAAR were $2.1 billion, a        41 percent decrease compared to the full year of 2009. The company        continues to experience a significant decline in COZAAR\/HYZAAR sales        since these medicines have lost marketing exclusivity in the United        States and in major European markets.     <\/p>\n<p>       <i>Neuroscience and Ophthalmology<\/i>     <\/p>\n<p>       Global sales of MAXALT (rizatriptan benzoate), Merck&#8217;s tablet for the        acute treatment of migraine, were $149 million for the fourth quarter of        2010, a 5 percent decrease from the same quarter last year. MAXALT        reported global sales of $550 million for the full year of 2010, a 4        percent decrease from the full year 2009.     <\/p>\n<p>       Sales of BRIDION (sugammadex), for the reversal of certain muscle        relaxants during surgery, were $40 million in the fourth quarter of 2010        and $103 million for the full year of 2010. BRIDION is currently        launching in more than 30 countries outside of the United States.     <\/p>\n<p>       <i>Oncology<\/i>     <\/p>\n<p>       Sales of TEMODAR (temozolomide), a treatment for certain types of brain        tumors, were $266 million for the fourth quarter and $1.1 billion for        the full year of 2010.     <\/p>\n<p>       Global sales of EMEND (aprepitant), a treatment for chemotherapy-induced        nausea and vomiting, were $110 million for the fourth quarter, an        increase of 23 percent compared with the same quarter of 2009, and $378        million for full year 2010, an increase of 19 percent compared with the        same period last year.     <\/p>\n<p>       Sales of CAELYX (pegylated liposomal doxorubicin hydrochloride) for the        treatment of ovarian cancer, metastatic breast cancer and Kaposi&#8217;s        sarcoma, were $75 million for the fourth quarter and $284 million for        the full year of 2010. As previously disclosed, marketing rights for        CAELYX returned to Johnson &amp; Johnson on Dec. 31, 2010.     <\/p>\n<p>       <i>Vaccines<\/i><sup><i>10<\/i><\/sup>     <\/p>\n<p>       Total sales as recorded by Merck of its cervical cancer vaccine,        GARDASIL (human papillomavirus (HPV) quadrivalent (types 6, 11, 16, 18)        vaccine, recombinant), were $221 million for the fourth quarter of 2010,        a 20 percent decrease from the same quarter in 2009. The decrease is        primarily a result of a government purchase for the CDC Strategic        National Stockpile in the fourth quarter 2009. Worldwide sales of        GARDASIL for the year were $988 million, a 12 percent decrease compared        with the prior year.     <\/p>\n<p>       Worldwide sales of Merck&#8217;s other viral vaccines, which include VARIVAX        (varicella virus vaccine live), M-M-R II (measles, mumps and rubella        virus vaccine live) and PROQUAD (measles, mumps, rubella and varicella        virus vaccine live), as recorded by Merck, were $285 million for the        fourth quarter of 2010, a decrease of 14 percent compared with the same        period a year earlier. The decrease is primarily a result of a 2009        government purchase of VARIVAX for the CDC Strategic National Stockpile.        Sales of other viral vaccines for the year were $1.4 billion, an        increase of 1 percent over full year 2009.     <\/p>\n<p>       ZOSTAVAX (zoster vaccine live), the company\u2019s vaccine to help prevent        shingles (herpes zoster), recorded sales of $107 million for the fourth        quarter of 2010 compared with $76 million for the fourth quarter of        2009. Sales for the full year of 2010 were $243 million compared with        $277 million for 2009. Sales this quarter were driven by significant        backorder fulfillment. Product backorders are expected to continue        through at least the first quarter of 2011 and the company anticipates        sales in future quarters will be affected by availability of supply.     <\/p>\n<p>       <i>Women&#8217;s Health and Endocrine<\/i>     <\/p>\n<p>       Global sales of NUVARING (etonogestrel\/ethinyl estradiol) vaginal ring,        a contraceptive product, were $145 million for the fourth quarter and        $559 million for the full year of 2010.     <\/p>\n<p>       Sales of FOLLISTIM AQ (follitropin beta injection), a fertility        treatment, were $138 million for the fourth quarter and $528 million for        the full year of 2010.     <\/p>\n<p>       <b>Product Performance \u2015 Animal Health<\/b>     <\/p>\n<p>       Animal Health sales totaled $815 million for the fourth quarter and $2.9        billion for the full year of 2010, reflecting continued solid        performance among ruminant and swine products. Animal Health includes        pharmaceutical and vaccine products for the prevention, treatment and        control of disease in all major farm and companion animal species. Merck        and sanofi-aventis continue the process of forming the proposed Animal        Health joint venture and expect to close the transaction in the first        half of 2011.     <\/p>\n<p>       <b>Product Performance \u2015 Consumer Care<\/b>     <\/p>\n<p>       Consumer Care sales were $251 million for the fourth quarter and $1.3        billion for the full year of 2010, which reflect continued strong        performance of a number of key brands including DR. SCHOLL&#8217;s and        COPPERTONE. Consumer Care includes footcare and suncare consumer        products, and a variety of over-the-counter medicines.     <\/p>\n<p>       <b>Total Employees<\/b>     <\/p>\n<p>       As of Dec. 31, 2010, Merck had approximately 94,000 employees worldwide.     <\/p>\n<p>       <b>Explanatory Note<\/b>     <\/p>\n<p>       Supplemental combined non-GAAP sales are provided on page 4 and in the        attached schedules at the end of this news release to reflect the        revenues of the company&#8217;s product sales on a comparable basis to periods        prior to the merger. Merck has defined supplemental combined non-GAAP        sales as GAAP sales adjusted to reflect a full quarter and full year of        Merck and Schering-Plough performance as if the merger closed at the        beginning of the periods indicated in the applicable table. This        supplemental information is provided to enhance investors&#8217; understanding        of the company&#8217;s products and overall business performance. This        information should be considered in addition to, but not in lieu of,        sales recorded in accordance with GAAP. Supplemental combined non-GAAP        sales are available in Tables 3 and 3a as part of this news release, and        additional information is included in the 8-K filing today.     <\/p>\n<p>       <b>Earnings Conference Call<\/b>     <\/p>\n<p>       Investors are invited to a live audio webcast of Merck&#8217;s fourth quarter        earnings conference call today at 8:00 a.m. EST by visiting Merck&#8217;s Web        site, <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2Finvestors%2Fevents-and-presentations%2Fhome.html&amp;esheet=6597162&amp;lan=en-US&amp;anchor=www.merck.com%2Finvestors%2Fevents-and-presentations%2Fhome.html&amp;index=1&amp;md5=b5e71632d831fb0afb43bf3e06c4ec5b\">www.merck.com\/investors\/events-and-presentations\/home.html<\/a>.        Institutional investors and analysts can participate in the call by        dialing (706) 758-9927 or (877) 381-5782. Journalists are invited to        listen in on the call by dialing (706) 758-9928 or (800) 399-7917. A        replay of the call will be available starting at 11 a.m. EST on Feb. 3        through 11:59 p.m. EST on Feb. 11. To listen to the replay, dial (706)        645-9291 or (800) 642-1687 and enter ID No. 30176534.     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships that        donate and deliver our products to the people who need them. For more        information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2F&amp;esheet=6597162&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=2&amp;md5=3cbc41371258bfc9e9ae3a7e1d325572\">www.merck.com<\/a>.     <\/p>\n<p>       <b>Forward-Looking Statement<\/b>     <\/p>\n<p>       This news release includes \u201cforward-looking statements\u201d within the        meaning of the safe harbor provisions of the United States Private        Securities Litigation Reform Act of 1995. Such statements may include,        but are not limited to, statements about the benefits of the merger        between Merck and Schering-Plough, including future financial and        operating results, the combined company\u2019s plans, objectives,        expectations and intentions and other statements that are not historical        facts. Such statements are based upon the current beliefs and        expectations of Merck\u2019s management and are subject to significant risks        and uncertainties. Actual results may differ from those set forth in the        forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that the expected synergies from the merger of Merck and        Schering-Plough will not be realized, or will not be realized within the        expected time period; the impact of pharmaceutical industry regulation        and health care legislation; the risk that the businesses will not be        integrated successfully; disruption from the merger making it more        difficult to maintain business and operational relationships; Merck\u2019s        ability to accurately predict future market conditions; dependence on        the effectiveness of Merck\u2019s patents and other protections for        innovative products; the risk of new and changing regulation and health        policies in the U.S. and internationally and the exposure to litigation        and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2009 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=6597162&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=28957bbaa7cc9275790e4ff790621d46\">www.sec.gov<\/a>).     <\/p>\n<p>       <sup>1<\/sup> Net loss attributable to Merck &amp; Co., Inc.     <\/p>\n<p>       <sup>2 <\/sup>Represents the difference between calculated GAAP EPS and        calculated non-GAAP EPS, which may be different than the amount        calculated by dividing the impact of the excluded items by the weighted        average shares.     <\/p>\n<p>       <sup>3 <\/sup>Merck is providing certain 2010 and 2009 non-GAAP        information in the charts on this page and in the charts on pages 5 and        6 related to expenses that excludes certain items because of the nature        of these items and the impact they have on the analysis of underlying        business performance and trends. Management believes that providing this        information enhances investors&#8217; understanding of the company&#8217;s        performance. This information should be considered in addition to, but        not in lieu of, information prepared in accordance with GAAP. For a        description of the items, see Tables 2a and 2b, including the related        footnotes, attached to this release.     <\/p>\n<p>       <sup>4 <\/sup>Amounts for the fourth quarter and full year of 2010        reflect $2.2 billion and $2.4 billion, respectively, of in-process        research and development impairment charges, including a charge of $1.7        billion to write-down the intangible asset related to vorapaxar recorded        in conjunction with the merger. The remaining amounts in 2010 and the        amounts in 2009 represent expenses for the amortization of intangible        assets and amortization of purchase accounting adjustments to        inventories recognized as a result of the merger.     <\/p>\n<p>       <sup>5 <\/sup>Includes an estimated income tax (benefit) expense on the        reconciling items. In addition, amounts for the full year of 2010        include a $391 million tax benefit from changes in a foreign entity&#8217;s        tax rate, which resulted in a reduction in deferred tax liabilities on        product intangibles recorded in conjunction with the merger, as well as        a $147 million tax charge related to U.S. health care reform legislation.     <\/p>\n<p>       <sup>6 <\/sup>Human Health includes worldwide prescription pharmaceutical        sales and consumer product sales excluding the U.S. and Canada. Consumer        Care includes U.S. and Canada consumer product sales.     <\/p>\n<p>       <sup>7 <\/sup>Other revenues are primarily comprised of alliance revenue,        miscellaneous corporate revenues and third party manufacturing sales.        Revenue from AstraZeneca LP recorded by Merck was $302 million in the        fourth quarter and $1.3 billion for the full year of 2010.     <\/p>\n<p>       <sup>8 <\/sup>Represents an estimated income tax (benefit) expense on the        reconciling items. on above items     <\/p>\n<p>       <sup>9<\/sup> COZAAR and HYZAAR are registered trademarks of E.I. duPont        de Nemours and Company, Wilmington, Del.     <\/p>\n<p>       <sup>10<\/sup> Vaccines in most major European markets are sold through        the company\u2019s joint venture, Sanofi Pasteur MSD, and the results from        the company&#8217;s interest in the joint venture are recorded in equity        income from affiliates.     <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"22\">\n<p class=\"bwcellpmargin\">             <b>MERCK &amp; CO., INC.<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>CONSOLIDATED STATEMENT OF OPERATIONS &#8211; GAAP<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>(UNAUDITED)<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Table 1<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"22\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"7\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>GAAP<\/b>           <\/p>\n<\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwnowrap bwpadr0 bwvertalignm bwalignc\" rowspan=\"3\">\n<p class=\"bwcellpmargin\">             <b>%<\/b><br \/><b>Change<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"7\" rowspan=\"2\">           <b>GAAP<\/b>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwnowrap bwpadr0 bwvertalignm bwalignc\" rowspan=\"3\">\n<p class=\"bwcellpmargin\">             <b>%<\/b><br \/><b>Change<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>4Q10<\/b>           <\/p>\n<\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\" rowspan=\"2\">           <b>4Q09<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\" colspan=\"3\" rowspan=\"2\">           <b>Full Year<\/b>            <\/p>\n<p class=\"bwcellpmargin\">             <b>2010<\/b>           <\/p>\n<\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\" colspan=\"3\" rowspan=\"2\">           <b>Full Year<\/b>            <\/p>\n<p class=\"bwcellpmargin\">             <b>2009<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Sales         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           12,094         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           10,093         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           20%         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           45,987         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           27,428         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           68%         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Costs, Expenses and Other         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3 bwvertalignt bwalignl\">           Materials and production <sup>(1)<\/sup>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           4,440         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           4,901         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -9%         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           18,396         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           9,019         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc\">           <b>*<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3 bwvertalignt bwalignl\">           Marketing and administrative <sup>(1)<\/sup>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,579         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,455         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           4%         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           13,245         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           8,543         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           55%         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3 bwvertalignt bwalignl\">           Research and development <sup>(1)<\/sup>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           4,517         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,971         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc\">           *         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           10,991         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           5,845         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           88%         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3 bwvertalignt bwalignl\">           Restructuring costs <sup>(2)<\/sup>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           121         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,490         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -92%         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           985         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,634         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -40%         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3 bwvertalignt bwalignl\">           Equity income from affiliates <sup>(3)<\/sup>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (171         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (374         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -54%         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (587         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (2,235         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -74%         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3 bwvertalignt bwalignl\">           Other (income) expense, net <sup>(4)<\/sup>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           309         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (7,813         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc\">           <b>*<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,304         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (10,668         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc\">           <b>*<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           (Loss) Income Before Taxes         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (701         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           6,463         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc\">           *         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,653         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           15,290         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -89%         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Income Tax (Benefit) Provision         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (201         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (60         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           671         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,268         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Net (Loss) Income         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (500         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           6,523         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc\">           *         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           982         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           13,022         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -92%         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"2\">           Less: Net Income Attributable to Noncontrolling Interests         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           31         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           29         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           121         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           123         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"2\">           Net (Loss) Income Attributable to Merck &amp; Co., Inc.         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (531         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           6,494         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc\">           *         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           861         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           12,899         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -93%         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"2\">           (Loss) Earnings per Common Share Assuming Dilution <sup>(5)<\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (0.17         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2.35         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc\">           *         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           0.28         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           5.65         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">           -95%         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"2\">           Average Shares Outstanding Assuming Dilution<sup> (6)<\/sup>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,081         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,753         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,120         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,273         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">           Tax Rate <sup>(7)<\/sup>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           28.7         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           -0.9         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           40.6         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           14.8         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           *\u2265 100%         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"22\">           (1) Amounts include the impact of purchase accounting adjustments,            restructuring costs and merger-related costs. See accompanying            tables for details.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"22\">           (2) Represents separation and other related costs associated with            restructuring activities.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"22\">           (3) In 2010, equity income from affiliates no longer reflects any            contribution from the Merck\/Schering-Plough partnership, which is            now wholly-owned by the company as a result of the merger, or from            Merial Limited due to the divesture of Merck\u2019s interest in September            2009.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"22\">           (4) Other (income) expense, net in the fourth quarter and full year            of 2010 includes $120 million and $200 million, respectively, of            exchange losses due to Venezuelan currency devaluations. Other            (income) expense, net for the full year of 2010 also includes a $950            million legal reserve and a $443 million gain recognized upon            AstraZeneca\u2019s exercise of the asset option. Other (income) expense,            net in the fourth quarter of 2009 includes a $7.5 billion gain            related to the Merck\/Schering-Plough partnership recognized in            connection with the merger. In addition, other (income) expense, net            for the full year of 2009 includes a $3.2 billion gain on the            divestiture of Merck\u2019s interest in Merial Limited. Other (income)            expense, net includes merger-related costs of $17 million for the            full year of 2010 and $23 million and $173 million for the fourth            quarter and full year of 2009, respectively.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"22\">           (5) The company calculates earnings per share pursuant to the            two-class method which requires the allocation of net income between            common shareholders and participating security holders (losses are            not allocated). Net income attributable to Merck &amp; Co., Inc. common            shareholders used to calculate earnings per common share assuming            dilution was $6,463 million for the fourth quarter of 2009 and was            $859 million and $12,853 million for the full year of 2010 and 2009,            respectively.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"22\">           (6) Because the company recorded a loss in the fourth quarter of            2010, no potential dilutive common shares were used in the            computation of loss per share assuming dilution as the effect would            have been anti-dilutive.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"22\">\n<p class=\"bwcellpmargin\">             (7) The GAAP effective tax rates for the fourth quarter and full              year of 2010 were 28.7% and 40.6%, respectively. Excluding the              impact of the non-GAAP items detailed in the accompanying tables,              the effective tax rates were 14.1% and 20.0% for the fourth              quarter and full year of 2010, respectively. The fourth quarter              and full year of 2010 GAAP and non-GAAP effective tax rates              reflect a benefit of approximately $80 million as a result of the              fourth quarter 2010 enactment of the tax extenders legislation,              including the R&amp;D tax credit.           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"22\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"22\">           The GAAP effective tax rates for the fourth quarter and full year of            2009 were (0.9)% and 14.8%, respectively. Excluding the impact of            the non-GAAP items detailed in the accompanying tables, the            effective tax rates were 15.3% and 20.0% for the fourth quarter and            full year of 2009, respectively. The fourth quarter and full year of            2009 GAAP and non-GAAP effective tax rates were impacted by the            favorable effect of tax settlements.         <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td colspan=\"24\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"24\">\n<p class=\"bwcellpmargin\">             <b>MERCK &amp; CO., INC.<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>CONSOLIDATED STATEMENT OF OPERATIONS<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>GAAP TO NON-GAAP RECONCILIATION<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>FOURTH QUARTER 2010<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>(UNAUDITED)<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Table 2a<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>GAAP<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Purchase<\/b><br \/><b> Accounting<\/b><sup>(1)<\/sup>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Restructuring<\/b><br \/><b> Costs <\/b><sup>(2)<\/sup>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Merger-Related<\/b><br \/><b> Costs <\/b><sup>(3)<\/sup>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Adjustment<\/b><br \/><b> Subtotal<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\" rowspan=\"2\">           <b>Non-GAAP<\/b>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Sales         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>12,094<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           12,094         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Materials and production         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>4,440<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,206         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           105         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,311         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,129         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Marketing and administrative         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>3,579<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           13         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           160         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           173         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,406         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Research and development         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>4,517<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,225         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           115         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,340         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,177         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Restructuring costs         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>121<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           121         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           121         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Equity income from affiliates         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>(171<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           <b>)<\/b>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (171         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Other (income) expense, net         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>309<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           309         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           (Loss) Income Before Taxes         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>(701<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           <b>)<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (3,431         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (354         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (160         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (3,945         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,244         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Income Tax (Benefit) Provision         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>(201<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           <b>)<\/b>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (658         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">\n<p class=\"bwcellpmargin\">             <sup>(4)<\/sup>           <\/p>\n<\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           457         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Net (Loss) Income         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>(500<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           <b>)<\/b>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (3,287         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,787         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Less: Net Income Attributable to Noncontrolling Interests         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>31<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           31         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Net (Loss) Income Attributable to Merck &amp; Co., Inc.         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>(531<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           <b>)<\/b>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (3,287         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,756         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">           (Loss) Earnings per Common Share Assuming Dilution         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>(0.17<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           <b>)<\/b>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           0.88         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwnowrap bwpadr0 bwvertalignb bwalignl\">\n<p class=\"bwcellpmargin\">             <sup>(5)<\/sup>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Average Shares Outstanding Assuming Dilution         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>3,081<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,106         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">           Tax Rate         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>28.7<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           <b>%<\/b>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           14.1         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"24\">           Merck is providing non-GAAP information that excludes certain items            because of the nature of these items and the impact they have on the            analysis of underlying business performance and trends. Management            believes that providing this information enhances investors&#8217;            understanding of the company&#8217;s performance. This information should            be considered in addition to, but not in lieu of, information            prepared in accordance with GAAP.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"24\">           (1) Amounts included in materials and production costs reflect            expenses for the amortization of intangible assets and the            amortization of purchase accounting adjustments to inventories            recognized as a result of the merger. Amounts included in research            and development expenses represent in-process research and            development (\u201cIPR&amp;D\u201d) impairment charges, including a $1.7 billion            charge to write-down the intangible asset related to vorapaxar.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"24\">           (2) Amounts primarily include employee separation costs and            accelerated depreciation associated with facilities to be closed or            divested.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"24\">           (3) Merger-related costs include transaction and integration costs            associated with the merger.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"24\">           (4) Represents the estimated tax impact on the reconciling items.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"24\">           (5) The company calculates earnings per share pursuant to the            two-class method which requires the allocation of net income between            common shareholders and participating security holders. Net income            attributable to Merck &amp; Co., Inc. common shareholders used to            calculate non-GAAP earnings per common share assuming dilution was            $2,746 million for the fourth quarter of 2010.         <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td colspan=\"27\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"27\">\n<p class=\"bwcellpmargin\">             <b>MERCK &amp; CO., INC.<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>CONSOLIDATED STATEMENT OF OPERATIONS<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>GAAP TO NON-GAAP RECONCILIATION<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>FULL YEAR 2010<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>(UNAUDITED)<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Table 2b<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"27\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"2\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\" rowspan=\"2\">           <b>GAAP<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Purchase<\/b><br \/><b> Accounting<\/b><sup>(1)<\/sup>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Restructuring<\/b><br \/><b> Costs <\/b><sup>(2)<\/sup>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Merger-Related<\/b><br \/><b>Costs <\/b><sup>(3)<\/sup>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"2\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Certain Other<\/b><br \/><b> Items <\/b><sup>(4)<\/sup>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Adjustment<\/b><br \/><b> Subtotal<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"3\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Non-GAAP<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Sales         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>45,987<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           45,987         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Materials and production         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>18,396<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           6,566         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           430         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           6,996         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           11,400         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Marketing and administrative         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>13,245<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           143         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           379         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           522         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           12,723         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Research and development         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>10,991<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,441         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           428         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,869         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           8,122         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Restructuring costs         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>985<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           985         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           985         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Equity income from affiliates         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>(587<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           <b>)<\/b>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (587         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Other (income) expense, net         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,304<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           17         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           507         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           524         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           780         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Income Before Taxes         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,653<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (9,007         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (1,986         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (396         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (507         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (11,896         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           13,549         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Taxes on Income         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>671<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (2,042         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">\n<p class=\"bwcellpmargin\">             <sup>(5)<\/sup>           <\/p>\n<\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,713         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           Net Income         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>982<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (9,854         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           10,836         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"2\">           Less: Net Income Attributable to Noncontrolling Interests         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>121<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td colspan=\"3\">         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8211;         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           121         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"2\">           Net Income Attributable to Merck &amp; Co., Inc.         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>861<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           (9,854         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl\">           )         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           10,715         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\" colspan=\"2\">           Earnings per Common Share Assuming Dilution         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>$<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>0.28<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           $         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           3.42         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwnowrap bwpadr0 bwvertalignb bwalignl\">\n<p class=\"bwcellpmargin\">             <sup>(6)<\/sup>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\" colspan=\"3\">           \u00a0         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"2\">           Average Shares Outstanding Assuming Dilution         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>3,120<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,120         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadb1 bwvertalignt bwalignl\">           Tax Rate         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           <b>40.6<\/b>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           <b>%<\/b>         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           20.0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">           %         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"27\">           Merck is providing non-GAAP information that excludes certain items            because of the nature of these items and the impact they have on the            analysis of underlying business performance and trends. Management            believes that providing this information enhances investors&#8217;            understanding of the company&#8217;s performance. This information should            be considered in addition to, but not in lieu of, information            prepared in accordance with GAAP.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"27\">           (1) Amounts included in materials and production costs reflect            expenses for the amortization of intangible assets and the            amortization of purchase accounting adjustments to inventories            recognized as a result of the merger. Amounts included in research            and development expenses represent in-process research and            development (\u201cIPR&amp;D\u201d) impairment charges, including a $1.7 billion            charge to write-down the intangible asset related to vorapaxar.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"27\">           (2) Amounts primarily include employee separation costs and            accelerated depreciation associated with facilities to be closed or            divested.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"27\">           (3) Merger-related costs include transaction and integration costs            associated with the merger.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"27\">           (4) Included in other (income) expense, net is a $950 million legal            reserve and a $443 million gain recognized upon AstraZeneca&#8217;s            exercise of the asset option.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"27\">           (5) Includes a $391 million tax benefit from changes in a foreign            entity&#8217;s tax rate, a charge of $147 million associated with a change            in tax law enacted as part of U.S. health care reform legislation,            as well as the estimated tax impact on the other reconciling items.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"2\">         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td colspan=\"3\">         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"27\">           6) The company calculates earnings per share pursuant to the            two-class method which requires the allocation of net income between            common shareholders and participating security holders. Net income            attributable to Merck &amp; Co., Inc. common shareholders used to            calculate non-GAAP earnings per common share assuming dilution was            $10,673 million for the full year of 2010.         <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"11\">\n<p class=\"bwcellpmargin\">             <b>MERCK &amp; CO., INC.<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>FRANCHISE \/ KEY PRODUCT SALES<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>FOURTH QUARTER 2010<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>(AMOUNTS IN MILLIONS)<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Table 3<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"11\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"11\">           The following Table reflects Supplemental Combined Non-GAAP sales            for the prior year which were adjusted to reflect a full quarter of            Merck and Schering-Plough combined results as if the merger closed            as of January 1, 2009.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>GAAP<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\" rowspan=\"2\">           <b>GAAP<\/b>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\" rowspan=\"2\">           <b>Adjustment<\/b>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Supp. Comb.<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Non-GAAP<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwpadb1 bwnowrap bwpadr0 bwvertalignt bwalignc\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>% Change<\/b><br \/><b> (4Q10 GAAP vs Supp.<\/b><br \/><b> Comb.              Non-GAAP 4Q09)<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">           <b>4Q10<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">           <b>4Q09<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">           <b>4Q09<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">           <b>4Q09<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           <b>TOTAL SALES <\/b><sup><b>(1)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$12,094<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$10,093<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$2,123<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$12,216<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>-1<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2 bwvertalignt bwalignl\">           <b>HUMAN HEALTH <\/b><sup><b>(2)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>10,581<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>9,072<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,733<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>10,805<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>-2<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Bone, Resp., Imm., &amp; Dermatology<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Singulair         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,349         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,260         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,260         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           7         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Remicade         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           710         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           431         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           205         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           635         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           12         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Nasonex         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           303         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           165         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           121         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           286         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           6         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Fosamax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           234         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           285         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           285         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -18         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Clarinex         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           146         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           101         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           55         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           155         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -6         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Arcoxia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           115         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           98         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           98         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           17         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Proventil         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           55         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           26         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           30         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           56         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -2         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Asmanex         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           53         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           37         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           21         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           58         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -8         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Cardiovascular<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Zetia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           629         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           399         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           215         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           614         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Vytorin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           562         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           384         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           194         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           577         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -3         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Integrilin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           63         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           46         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           26         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           72         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -12         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Diabetes &amp; Obesity<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Januvia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           675         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           558         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           558         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           21         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Janumet         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           288         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           202         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           202         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           42         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Infectious Disease<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Isentress         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           313         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           234         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           234         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           34         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           PegIntron         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           198         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           149         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           67         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           216         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -8         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Cancidas         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           174         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           175         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           175         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8212;         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Primaxin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           158         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           196         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           196         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -19         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Invanz         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           113         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           88         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           88         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           29         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Avelox         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           92         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           66         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           52         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           118         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -22         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Rebetol         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           54         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           36         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           21         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           57         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -4         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Crixivan \/ Stocrin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           58         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           52         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           52         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           11         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Diversified Brands<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Cozaar \/ Hyzaar         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           415         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           955         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           955         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -57         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Zocor         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           121         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           139         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           139         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -13         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Propecia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           124         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           123         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           123         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Claritin Rx         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           122         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           71         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           38         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           109         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           11         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Vasotec \/ Vaseretic         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           64         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           85         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           85         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -25         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Remeron         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           62         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           38         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           21         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           60         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           5         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Proscar         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           44         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           72         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           72         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -39         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Neurosciences &amp; Ophthalmology<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Maxalt         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           149         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           156         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           156         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -5         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Cosopt \/ Trusopt         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           131         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           134         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           134         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -2         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Subutex \/ Suboxone         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           36         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           20         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           56         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -98         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Oncology<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Temodar         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           266         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           188         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           103         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           292         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -9         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Emend         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           110         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           89         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           89         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           23         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Caelyx         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           75         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           47         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           24         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           70         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           7         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Intron A         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           54         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           38         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           16         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           54         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -1         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Vaccines<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           ProQuad, M-M-R II and Varivax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           285         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           333         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           333         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -14         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Gardasil         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           221         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           277         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           277         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -20         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           RotaTeq         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           169         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           135         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           135         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           25         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Pneumovax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           156         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           128         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           128         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           22         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Zostavax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           107         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           76         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           76         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           41         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Women&#8217;s Health &amp; Endocrine<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           NuvaRing         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           145         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           88         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           47         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           135         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           7         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Follistim AQ         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           138         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           96         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           53         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           149         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -7         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Implanon         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           71         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           37         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           16         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           53         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           34         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Cerazette         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           49         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           35         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           18         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           53         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -8         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Other Human Health <\/b><sup><b>(3)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,160         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           708         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           372         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,079         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           8         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           <b>ANIMAL HEALTH<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>815<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>494<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>265<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>759<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>7<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           <b>CONSUMER CARE <\/b><sup><b>(2)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>251<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>149<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>83<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>232<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>8<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           Claritin OTC         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           67         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           39         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           25         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           63         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           6         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           <b>Other Revenues <\/b><sup><b>(4)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>447<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>379<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>41<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>420<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>6<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           Astra         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           302         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           332         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           332         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -9         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"11\">           <sup>(1)<\/sup> Only select products are shown.         <\/td>\n<\/tr>\n<tr>\n<td colspan=\"11\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"11\">           <sup>(2) <\/sup>Human Health includes worldwide prescription            pharmaceutical sales and consumer product sales excluding the US and            Canada. Consumer Care includes US and Canada consumer product sales.         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"11\">           <sup>(3)<\/sup> Includes Human Health products not individually shown            above. Other Vaccines sales included in Other Human Health were $75            million and $50 million for fourth quarter 2010 and 2009,            respectively.         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"11\">           <sup>(4) <\/sup>Other revenues are primarily comprised of alliance            revenue, miscellaneous corporate revenues and third party            manufacturing sales.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"11\">           Note: The company is providing Supplemental Combined Non-GAAP sales            to reflect the revenues of the company&#8217;s product sales on a            comparable basis to periods prior to the merger. Merck has defined            Supplemental Combined Non-GAAP sales as GAAP sales adjusted to            reflect a full quarter of Merck and Schering-Plough performance as            if the merger closed at the beginning of the periods indicated in            this table. This supplemental information is provided to enhance            investors&#8217; understanding of the company&#8217;s sales performance. This            information should be considered in addition to, but not in lieu of,            sales reported in accordance with GAAP.         <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc\" colspan=\"11\">\n<p class=\"bwcellpmargin\">             <b>MERCK &amp; CO., INC.<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>FRANCHISE \/ KEY PRODUCT SALES<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>FULL YEAR 2010<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>(AMOUNTS IN MILLIONS)<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Table 3a<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"11\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"11\">           The following Table reflects Supplemental Combined Non-GAAP sales            for the prior year which were adjusted to reflect the period of            Merck and Schering-Plough combined results as if the merger closed            as of January 1, 2009.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>GAAP<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\" rowspan=\"2\">           <b>GAAP<\/b>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\" rowspan=\"2\">           <b>Adjustment<\/b>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignc bwsinglebottom\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">             <b>Supp. Comb.<\/b>           <\/p>\n<p class=\"bwcellpmargin\">             <b>Non-GAAP<\/b>           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" rowspan=\"3\">\n<p class=\"bwcellpmargin\">             <b>% Change<\/b><br \/><b> (FY 10 GAAP vs<\/b><br \/><b> Supp. Comb.              Non-<\/b><br \/><b>GAAP FY 09)<\/b>           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">           <b>Full Year 10<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">           <b>Full Year 09<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">           <b>Full Year 09<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">           <b>Full Year 09<\/b>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           <b>TOTAL SALES <\/b><sup><b>(1)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$45,987<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$27,428<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$18,537<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>$45,964<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>&#8212;<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2 bwvertalignt bwalignl\">           <b>HUMAN HEALTH <\/b><sup><b>(2)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>39,811<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>25,236<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>14,862<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>40,098<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>-1<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Bone, Resp., Imm., &amp; Dermatology<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Singulair         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           4,987         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           4,660         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           4,660         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           7         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Remicade         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,714         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           431         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,896         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,327         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           17         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Nasonex         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,220         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           165         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,014         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,179         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Fosamax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           926         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,100         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,100         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -16         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Clarinex         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           659         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           101         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           619         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           719         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -8         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Arcoxia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           398         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           358         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           358         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           11         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Proventil         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           210         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           26         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           198         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           225         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -7         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Asmanex         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           208         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           37         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           177         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           214         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -3         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Cardiovascular<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Zetia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,297         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           403         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,841         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,244         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Vytorin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,014         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           441         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,671         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,112         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -5         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Integrilin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           266         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           46         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           249         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           295         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -10         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Diabetes &amp; Obesity<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Januvia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,385         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,922         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,922         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           24         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Janumet         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           954         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           658         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           658         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           45         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Infectious Disease<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Isentress         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,090         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           752         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           752         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           45         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           PegIntron         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           737         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           149         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           696         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           844         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -13         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Cancidas         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           611         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           617         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           617         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -1         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Primaxin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           610         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           689         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           689         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -11         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Invanz         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           362         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           293         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           293         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           24         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Avelox         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           316         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           66         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           302         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           368         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -14         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Rebetol         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           221         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           36         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           218         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           254         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -13         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Crixivan \/ Stocrin         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           206         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           206         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           206         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           &#8212;         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Diversified Brands<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Cozaar \/ Hyzaar         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,104         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,561         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           3,561         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -41         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Zocor         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           468         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           558         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           558         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -16         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Propecia         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           447         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           440         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           440         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Claritin Rx         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           420         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           71         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           362         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           433         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -3         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Vasotec \/ Vaseretic         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           255         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           311         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           311         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -18         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Remeron         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           223         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           38         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           195         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           234         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -5         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Proscar         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           216         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           291         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           291         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -26         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Neurosciences &amp; Ophthalmology<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Maxalt         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           550         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           575         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           575         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -4         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Cosopt \/ Trusopt         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           484         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           503         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           503         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -4         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Subutex \/ Suboxone         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           111         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           36         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           175         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           211         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -47         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Oncology<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Temodar         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,065         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           188         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           885         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,073         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -1         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Emend         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           378         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           317         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           317         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           19         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Caelyx         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           284         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           47         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           219         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           265         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           7         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Intron A         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           209         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           38         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           192         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           231         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -9         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Vaccines<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           ProQuad, M-M-R II and Varivax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,378         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,369         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,369         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Gardasil         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           988         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,118         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,118         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -12         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           RotaTeq         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           519         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           522         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           522         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -1         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Pneumovax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           376         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           346         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           346         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           9         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Zostavax         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           243         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           277         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           277         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -12         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           <b>Women&#8217;s Health &amp; Endocrine<\/b>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           NuvaRing         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           559         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           88         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           422         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           511         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           9         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Follistim AQ         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           528         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           96         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           450         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           546         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -3         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Implanon         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           236         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           37         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           142         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           179         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           32         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl6 bwvertalignt bwalignl\">           Cerazette         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           209         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           35         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           153         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           187         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           11         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           <b>Other Human Health <\/b><sup><b>(3)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           4,170         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,218         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           2,787         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           4,005         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           4         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           <b>ANIMAL HEALTH<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>2,941<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>494<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>2,222<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>2,716<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>8<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           <b>CONSUMER CARE <\/b><sup><b>(2)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,342<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>149<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,131<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,281<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>5<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           Claritin OTC         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           401         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           39         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           367         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           406         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -1         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">           <b>Other Revenues <\/b><sup><b>(4)<\/b><\/sup>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,893<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,548<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>322<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1,870<\/b>         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           <b>1<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl4 bwvertalignt bwalignl\">           Astra         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,252         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,414         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwvertalignb bwalignr\">\n<p class=\"bwcellpmargin\">             \u00a0           <\/p>\n<\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           1,414         <\/td>\n<td>         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr\">           -11         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"11\">           <sup>(1)<\/sup> Only select products are shown.         <\/td>\n<\/tr>\n<tr>\n<td colspan=\"11\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"11\">           <sup>(2) <\/sup>Human Health includes worldwide prescription            pharmaceutical sales and consumer product sales excluding the US and            Canada. Consumer Care includes US and Canada consumer product sales.         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"11\">           <sup>(3)<\/sup> Includes Human Health products not individually shown            above. Other Vaccines sales included in Other Human Health were $282            million and $188 million for the full year 2010 and 2009,            respectively.         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"11\">           <sup>(4) <\/sup>Other revenues are primarily comprised of alliance            revenue, miscellaneous corporate revenues and third party            manufacturing sales.         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"11\">           Note: The company is providing Supplemental Combined Non-GAAP sales            to reflect the revenues of the company&#8217;s product sales on a            comparable basis to periods prior to the merger. Merck has defined            Supplemental Combined Non-GAAP sales as GAAP sales adjusted to            reflect the full year of Merck and Schering-Plough performance as if            the merger closed at the beginning of the periods indicated in this            table. This supplemental information is provided to enhance            investors&#8217; understanding of the company&#8217;s sales performance. This            information should be considered in addition to, but not in lieu of,            sales reported in accordance with GAAP.         <\/td>\n<\/tr>\n<\/table>\n<p><p>       Merck &amp; Co., Inc.<br \/>Media Contacts:<br \/>David Caouette,        908-423-3461<br \/>Steven Campanini, 908-423-4291<br \/>or<br \/>Investor        Contacts:<br \/>Alex Kelly, 908-423-5185<br \/>Joe Romanelli, 908-423-5088     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company Reports Double-Digit Non-GAAP EPS Growth in the Fourth Quarter Fourth Quarter Non-GAAP EPS of $0.88, Excluding Certain Items; GAAP EPS of $(0.17); Full Year 2010 Non-GAAP EPS of $3.42, Excluding Certain Items; GAAP EPS of $0.28 Continued Strong Global Growth from JANUVIA\/JANUMET, SINGULAIR, ISENTRESS, REMICADE Realized More than $2 Billion in Net Synergy Savings in 2010; On Track to Reach $3.5 Billion in Annual Savings by End of 2012 Company Withdraws Previous Long-Term Non-GAAP EPS Target; Full Year 2011 Non-GAAP EPS Target of $3.64 to $3.76, Excluding Certain Items; GAAP EPS Range of $2.05 to $2.33 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses. The<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[52,289],"class_list":["post-742143","news_item","type-news_item","status-publish","hentry","tag-financial-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Fourth Quarter and Full Year 2010 Financial Results - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fourth-quarter-and-full-year-2010-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Fourth Quarter and Full Year 2010 Financial Results - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Company Reports Double-Digit Non-GAAP EPS Growth in the Fourth Quarter Fourth Quarter Non-GAAP EPS of $0.88, Excluding Certain Items; GAAP EPS of $(0.17); Full Year 2010 Non-GAAP EPS of $3.42, Excluding Certain Items; GAAP EPS of $0.28 Continued Strong Global Growth from JANUVIA\/JANUMET, SINGULAIR, ISENTRESS, REMICADE Realized More than $2 Billion in Net Synergy Savings in 2010; On Track to Reach $3.5 Billion in Annual Savings by End of 2012 Company Withdraws Previous Long-Term Non-GAAP EPS Target; Full Year 2011 Non-GAAP EPS Target of $3.64 to $3.76, Excluding Certain Items; GAAP EPS Range of $2.05 to $2.33 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses. The\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fourth-quarter-and-full-year-2010-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"29 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fourth-quarter-and-full-year-2010-financial-results\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fourth-quarter-and-full-year-2010-financial-results\\\/\",\"name\":\"Merck Announces Fourth Quarter and Full Year 2010 Financial Results - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2011-02-03T07:00:00+00:00\",\"dateModified\":\"2026-08-10T17:01:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fourth-quarter-and-full-year-2010-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fourth-quarter-and-full-year-2010-financial-results\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fourth-quarter-and-full-year-2010-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Fourth Quarter and Full Year 2010 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Fourth Quarter and Full Year 2010 Financial Results - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fourth-quarter-and-full-year-2010-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Fourth Quarter and Full Year 2010 Financial Results - Merck.com","og_description":"Company Reports Double-Digit Non-GAAP EPS Growth in the Fourth Quarter Fourth Quarter Non-GAAP EPS of $0.88, Excluding Certain Items; GAAP EPS of $(0.17); Full Year 2010 Non-GAAP EPS of $3.42, Excluding Certain Items; GAAP EPS of $0.28 Continued Strong Global Growth from JANUVIA\/JANUMET, SINGULAIR, ISENTRESS, REMICADE Realized More than $2 Billion in Net Synergy Savings in 2010; On Track to Reach $3.5 Billion in Annual Savings by End of 2012 Company Withdraws Previous Long-Term Non-GAAP EPS Target; Full Year 2011 Non-GAAP EPS Target of $3.64 to $3.76, Excluding Certain Items; GAAP EPS Range of $2.05 to $2.33 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses. The","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fourth-quarter-and-full-year-2010-financial-results\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:19+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"29 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fourth-quarter-and-full-year-2010-financial-results\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fourth-quarter-and-full-year-2010-financial-results\/","name":"Merck Announces Fourth Quarter and Full Year 2010 Financial Results - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2011-02-03T07:00:00+00:00","dateModified":"2026-08-10T17:01:19+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fourth-quarter-and-full-year-2010-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fourth-quarter-and-full-year-2010-financial-results\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fourth-quarter-and-full-year-2010-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Fourth Quarter and Full Year 2010 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"296acb4a-071b-4571-abc1-5511627077a9","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742143\/revisions"}],"predecessor-version":[{"id":3679279,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742143\/revisions\/3679279"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742143"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}